Cost-effectiveness of the CNIC-polypill strategy for the secondary prevention of CV disease in male and female patients with established coronary heart disease based on improved risk factor control

被引：0
|
作者：
Aguiar, C. [1 ]
Araujo, F. [2 ]
Rubio, G. [3 ]
Carcedo, D. [4 ]
Abreu-Oliveira, T. P. [5 ]
Paz, S. [6 ]
Castellano, J. M. [7 ]
Fuster, V. [8 ]
机构：
[1] Hosp Santa Cruz, Serv Cardiol, Carnaxide, Portugal
[2] Hosp Lusiadas, Serv Med Interna, Lisbon, Portugal
[3] Ferrer Int, Barcelona, Spain
[4] Hygeia Consulting, Madrid, Spain
[5] Ferrer Portugal, Lisbon, Portugal
[6] Smartwriting4u, Benicassim, Spain
[7] Natl Ctr Cardiovasc Res CNIC, Madrid, Spain
[8] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2552 / 2552
页数：1
相关论文
共 39 条
  • [1] Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
    Aguiar, Carlos
    Araujo, Francisco
    Rubio-Mercade, Gabriel
    Carcedo, David
    Paz, Silvia
    Castellano, Jose Maria
    Fuster, Valentin
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2022, 9 (02): : 134 - 146
  • [2] COST-EFFECTIVENESS OF THE CNIC POLYPILL - FIXED DOSE COMBINATION OF ACETYLSALICYLIC ACID, RAMIPRIL AND ATORVASTATIN - FOR THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN GREECE
    Ntaios, G.
    Vemmos, K.
    Papapetrou, P.
    Zafeiri, S.
    Rubio, G.
    VALUE IN HEALTH, 2019, 22 : S550 - S550
  • [3] The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease
    Gillespie, Paddy
    O'Shea, Eamon
    Murphy, Andrew W.
    Byrne, Mary C.
    Byrne, Molly
    Smith, Susan M.
    Cupples, Margaret E.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2010, 26 (03) : 263 - 271
  • [4] COST-EFFECTIVENESS OF ASPIRIN IN SECONDARY PREVENTION OF CORONARY HEART-DISEASE
    GASPOZ, JM
    GOLDMAN, P
    WILLIAMS, L
    WEINSTEIN, M
    GOLDMAN, L
    CIRCULATION, 1995, 92 (08) : 219 - 219
  • [5] Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care
    Turner, D. A.
    Paul, S.
    Stone, M. A.
    Juarez-Garcia, A.
    Squire, I.
    Khunti, K.
    HEART, 2008, 94 (12) : 1601 - 1606
  • [6] Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
    Becerra, Virginia
    Gracia, Alfredo
    Desai, Kamal
    Abogunrin, Seye
    Brand, Sarah
    Chapman, Ruth
    Garcia Alonso, Fernando
    Fuster, Valentin
    Sanz, Gines
    BMJ OPEN, 2015, 5 (05):
  • [7] Cost-Effectiveness of a Home Based Intervention for Secondary Prevention of Readmission with Chronic Heart Disease
    Byrnes, Joshua
    Carrington, Melinda
    Chan, Yih-Kai
    Pollicino, Christine
    Dubrowin, Natalie
    Stewart, Simon
    Scuffham, Paul A.
    PLOS ONE, 2015, 10 (12):
  • [8] Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model
    Muls, E
    Van Ganse, E
    Closon, MC
    ATHEROSCLEROSIS, 1998, 137 : S111 - S116
  • [9] CONTINOUS IMPROVEMENT OF TREATABLE CARDIOVASCULAR RISK FACTORS CONTROL IN SECONDARY PREVENTION OF ESTABLISHED CORONARY HEART DISEASE
    Bruthans, Jan
    Bruthans, Jan
    Mayer, Otto
    Sulc, Pavel
    JOURNAL OF HYPERTENSION, 2018, 36 : E205 - E205
  • [10] COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITION FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART-DISEASE
    GOLDMAN, L
    WEINSTEIN, MC
    GOLDMAN, PA
    WILLIAMS, LW
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (09): : 1145 - 1151
1234